Neogen Toekomstige groei
Future criteriumcontroles 0/6
De omzet van Neogen zal naar verwachting dalen met 1.3% per jaar, terwijl de jaarlijkse winst naar verwachting zal groeien met 76.2% per jaar. De winst per aandeel zal naar verwachting groeien met 76.4% per jaar.
Belangrijke informatie
76.2%
Groei van de winst
76.43%
Groei van de winst per aandeel
| Medical Equipment winstgroei | 16.3% |
| Inkomstengroei | -1.3% |
| Toekomstig rendement op eigen vermogen | n/a |
| Dekking van analisten | Low |
| Laatst bijgewerkt | 08 Jun 2026 |
Recente toekomstige groei-updates
Recent updates
Narratiefupdate • Jun 23
NEOG: Screwworm Response And Buybacks Will Support Bullish 2026 Outlook
Analysts have modestly revised their Neogen price target to $13.00, reflecting updated assumptions around a slightly lower discount rate, softer revenue growth expectations, reduced profit margins, and a higher future P/E multiple in their valuation models. What's in the News for Neogen Neogen expanded FIFRA Section 2(ee) recommendations for its Prozap Insectrin X Concentrate and Prozap Screw Worm and Ear Tick Aerosol products to support New World Screwworm response efforts in livestock, with approvals in Texas and availability in Florida.
Narratiefupdate • Jun 08
NEOG: Food Safety Execution And Manufacturing Shift Will Support Future Upside
Analysts have raised their price target on Neogen to $11.00. This reflects updated assumptions that include a slightly lower discount rate, a smaller expected decline in revenue growth, a marginally higher profit margin, and a modestly reduced future P/E multiple.Narratiefupdate • May 25
NEOG: Raised 2026 Revenue Guidance And Higher P/E Expectation Will Support Upside
Analysts have raised their price target for Neogen to $11.00 from $10.00, citing updated assumptions around discount rates, revenue trends, profit margins, and a higher expected future P/E multiple. What's in the News Neogen issued updated guidance for fiscal 2026, focusing on its outlook for full year revenue (Key Developments).
Narratiefupdate • Apr 30
NEOG: Updated 2026 Revenue Outlook Will Support Future Upside Potential
Analysts have nudged their price target on Neogen slightly higher to $12, reflecting updated assumptions around discount rate, profit margin and future P/E that keep fair value broadly in line with prior estimates. What's in the News Neogen updated full fiscal year 2026 guidance, with projected revenue now in a range of $857 million to $860 million.Narratiefupdate • Apr 15
NEOG: Recall Response And Updated 2026 Guidance Will Support Future Upside
Analysts have raised their price target on Neogen from $11.67 to $12.00, citing updated assumptions around discount rates, revenue trends, profit margins, and a higher future P/E of 32.21 compared with 28.61 previously. What's in the News Neogen updated full fiscal year 2026 guidance, indicating expected revenue in a range of $857 million to $860 million, compared with prior guidance of $845 million to $855 million (corporate guidance).Narratiefupdate • Apr 01
NEOG: Earnings Outlook Will Benefit From Recall Actions And New Guidance
Analysts have raised their price target on Neogen from $8.17 to $11.67 per share, citing updated assumptions related to the discount rate, revenue growth, profit margins, and a higher future P/E multiple. What's in the News Neogen is voluntarily recalling all lots within expiry of Neogen Vet HYCOAT Hyaluronate Sodium Sterile Solution for dogs, cats, and horses at the veterinarian level due to microbial contamination identified in certain 10 mL / 50 mg vials.Narratiefupdate • Mar 18
NEOG: Recall Resolution Will Shape Bullish View On 2026 Revenue Outlook
Analysts have kept Neogen's price target steady at $13.00, indicating only minor adjustments in assumptions for discount rate, revenue growth, profit margin, and future P/E that do not materially change their overall view of the stock's valuation. What's in the News Neogen is voluntarily recalling all lots of Neogen Vet HYCOAT Hyaluronate Sodium Sterile Solution for dogs, cats, and horses at the veterinarian level due to microbial contamination identified in certain 10 mL / 50 mg vials, and is extending the recall to 2 mL / 20 mg vials while its investigation continues (Key Developments).Narratiefupdate • Mar 04
NEOG: 2026 Outlook Will Rely On Recall Resolution For Upside
Analysts are holding Neogen's fair value estimate at $13.00 while modestly adjusting their assumptions around the discount rate, long term revenue trends, profit margins, and future P/E. This reflects updated views on the company’s risk profile and earnings potential without changing the overall price target level.Narratiefupdate • Feb 18
NEOG: 2026 Revenue Outlook Will Support Continued Bullish Thesis
Analysts have maintained Neogen's price target at $13.00, noting that only minor adjustments to assumptions around discount rate, revenue growth, profit margins, and future P/E were made, which do not materially change their valuation view. What's in the News Neogen is voluntarily recalling all lots of Neogen Vet HYCOAT Hyaluronate Sodium Sterile Solution for dogs, cats, and horses at the veterinarian level, after microbial contamination was identified in certain 10 mL/50 mg vials used via intraarticular injection, which is inconsistent with the product's labeled use (Key Developments).Seeking Alpha • Feb 16
Neogen Corporation Could Re-Rate As 3M Food Safety Integration Improves
Summary Neogen Corporation’s sizeable $11 billion food-and-animal safety TAM still has secular tailwinds with regulation, traceability, and disease-prevention trends. Management believes this market has an overall projected 6%–7% CAGR through 2030. In that context, NEOG’s Petrifilm anchors future recurring consumables and end-to-end testing ecosystem. NEOG’s 3M Food Safety combination expanded scale but introduced integration frictions, which, going forward, are an interesting opportunity for management. If NEOG executes on its turnaround plan with better supply chains, fulfillment, and systems, it could unlock long-term shareholder value. Read the full article on Seeking AlphaNarratiefupdate • Feb 03
NEOG: Higher Forward P/E And 2026 Outlook Will Support Bullish Thesis
Analysts have raised their price target on Neogen by an implied $3 per share, pointing to adjustments in fair value, discount rate, revenue growth expectations, profit margin assumptions, and a higher forward P/E multiple as the key drivers behind the change. What's in the News Neogen is voluntarily recalling all lots within expiry of Neogen Vet HYCOAT Hyaluronate Sodium Sterile Solution for dogs, cats, and horses at the veterinarian level due to microbial contamination identified in certain 10 mL/50 mg vials, with an expanded recall to 2 mL/20 mg vials while the investigation continues (Key Developments).Analyseartikel • Feb 02
Improved Revenues Required Before Neogen Corporation (NASDAQ:NEOG) Stock's 46% Jump Looks Justified
Despite an already strong run, Neogen Corporation ( NASDAQ:NEOG ) shares have been powering on, with a gain of 46% in...Narratiefupdate • Jan 20
NEOG: Future CFO Transition And 2026 Guidance Will Support Measured Outlook
Analysts have raised their fair value estimate for Neogen from US$6.50 to US$10.00, reflecting updated assumptions regarding discount rates, revenue trends, profit margins and a higher future P/E multiple. What's in the News Neogen issued earnings guidance for fiscal 2026, with revenue anticipated in the range of US$845 million to US$855 million, giving investors a sense of management’s current expectations for the business (Key Developments).Narratiefupdate • Jan 05
NEOG: New CFO Appointment Will Support Confidence In Earnings Outlook
Analysts now place a higher implied value on Neogen, lifting their fair value estimate from US$8.00 to US$10.00, citing updated assumptions around discount rates, revenue trends, profit margins, and a richer future P/E multiple. What's in the News Neogen appointed Bryan Riggsbee as Chief Financial Officer, effective November 3, 2025.Analyseartikel • Dec 19
Neogen Corporation (NASDAQ:NEOG) Shares Fly 34% But Investors Aren't Buying For Growth
The Neogen Corporation ( NASDAQ:NEOG ) share price has done very well over the last month, posting an excellent gain of...Narratiefupdate • Dec 17
NEOG: Future CFO Transition And Guidance Stability Will Support Measured Outlook
Analysts have raised their price target on Neogen from approximately $5.00 to $6.50 per share, citing a slightly lower discount rate, modestly improved revenue trajectory, better profit margin expectations, and a willingness to assign a higher future P/E multiple. What's in the News Neogen appointed Bryan Riggsbee as Chief Financial Officer effective November 3, 2025, with outgoing CFO David Naemura supporting the transition through year end.Narratiefupdate • Dec 03
NEOG: CFO Transition And Alliance Renewal Will Support Future Earnings
Analysts have modestly raised their price target on Neogen by about $0.20 per share, citing a slightly higher assumed discount rate and marginally richer future valuation multiples that together offset minor tweaks to long term growth and margin expectations. What's in the News Reaffirmed fiscal 2026 earnings guidance, maintaining full-year revenue expectations of $820 million to $840 million (company guidance).Narratiefupdate • Nov 19
NEOG: Profit Margin Expansion And CFO Transition Will Drive Earnings Potential
Analysts have raised their price target for Neogen modestly, citing improved profit margin projections and a slightly lower expected future price-to-earnings ratio as key factors behind the adjustment. What's in the News Neogen appointed Bryan Riggsbee as its new Chief Financial Officer, effective November 3, 2025.Narratiefupdate • Oct 31
NEOG: Rising Profit Margins And New Partnerships Will Drive Future Expansion
Narrative Update: Neogen Analyst Price Target Revised Analysts have slightly raised their price target for Neogen, citing improvements in expected profit margins and a modest decline in projected future valuation multiples. This has resulted in a new estimated fair value of $8.17 per share.Narratiefupdate • Oct 17
Food Safety Testing Advances Will Expand Global Opportunities
Neogen's analyst target price has risen from $7.67 to $8.17, as analysts point to improved revenue growth projections alongside a reduced discount rate, both supporting a higher valuation. What's in the News Neogen introduced Molecular Detection Assay: Listeria Right Now, a rapid, enrichment-free tool for detecting Listeria species with results in about two hours and streamlined workflow benefits (Product-Related Announcements).Narratiefupdate • Oct 03
Food Safety Testing Advances Will Expand Global Opportunities
Analysts have raised their price target for Neogen from $6.50 to $7.67, citing a slightly lower discount rate and forward profit expectations. Revenue growth projections remain stable.Analyseartikel • Jul 10
Is Neogen (NASDAQ:NEOG) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Nieuw narratief • May 27
Food Safety And Genomics Will Expand Global Markets
Resilient core businesses, strategic divestitures, and efficiency initiatives are expected to stabilize revenue and expand margins as macro and operational conditions improve.Analyseartikel • May 16
Improved Revenues Required Before Neogen Corporation (NASDAQ:NEOG) Stock's 33% Jump Looks Justified
Those holding Neogen Corporation ( NASDAQ:NEOG ) shares would be relieved that the share price has rebounded 33% in the...Seeking Alpha • Apr 23
Neogen: A Fair Divestment (Rating Upgrade)
Summary Neogen's merger with 3M Food Safety led to significant debt and operational struggles, causing shares to plummet and the CEO to be ousted. Following disappointing sales and earnings, the company is exploring asset sales and restructuring, offering potential upside if stabilization occurs. Neogen's current valuation appears modest relative to sales, presenting a speculative opportunity for investors willing to take on risk. I am cautiously optimistic about Neogen's future, considering the potential for above-average returns if divestments are executed at reasonable valuations. Read the full article on Seeking AlphaAnalyseartikel • Apr 11
Here's Why Neogen (NASDAQ:NEOG) Is Weighed Down By Its Debt Load
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Jan 14
Neogen: Food Safety Play Is Far From A Safe Pay
Summary Neogen Corporation's merger with 3M Food Safety in 2022 led to significant challenges, including valuation compression, debt increase, and underperformance, causing shares to plummet. Neogen's financial performance has been disappointing, with sales and EBITDA falling short of expectations and net debt increasing. The company's guidance for 2025 remains modest, and recent results have shown minimal revenue growth and high leverage ratios, frustrating investors. Trading at $12, NEOG's future hinges on management's ability to execute and deliver on promised EBITDA improvements to reduce leverage and boost earnings. Read the full article on Seeking AlphaAnalyseartikel • Dec 03
Risks To Shareholder Returns Are Elevated At These Prices For Neogen Corporation (NASDAQ:NEOG)
It's not a stretch to say that Neogen Corporation's ( NASDAQ:NEOG ) price-to-sales (or "P/S") ratio of 3.3x right now...Analyseartikel • Nov 07
Does Neogen (NASDAQ:NEOG) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Seeking Alpha • Oct 11
Neogen Stock: Expect Volatility To Continue Amid Weak Growth
Summary Neogen reported its Q1 earnings, which missed expectations. Weak demand trends across food and animal safety end markets have pressured the sales outlook. We expect shares to remain volatile until there is evidence of a growth rebound. Read the full article on Seeking AlphaAnalyseartikel • Aug 28
Risks To Shareholder Returns Are Elevated At These Prices For Neogen Corporation (NASDAQ:NEOG)
Neogen Corporation's ( NASDAQ:NEOG ) price-to-sales (or "P/S") ratio of 4x may not look like an appealing investment...Analyseartikel • Jul 31
We Think Neogen (NASDAQ:NEOG) Is Taking Some Risk With Its Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 5/31/2029 | 809 | -26 | N/A | N/A | 1 |
| 5/31/2028 | 843 | -38 | N/A | N/A | 3 |
| 5/31/2027 | 849 | -53 | 59 | 109 | 4 |
| 5/31/2026 | 857 | -15 | -31 | 22 | 4 |
| 2/28/2026 | 871 | -609 | 6 | 69 | N/A |
| 11/30/2025 | 880 | -603 | -18 | 66 | N/A |
| 8/31/2025 | 887 | -1,043 | -3 | 87 | N/A |
| 5/31/2025 | 895 | -1,092 | -46 | 58 | N/A |
| 2/28/2025 | 906 | -485 | -44 | 69 | N/A |
| 11/30/2024 | 914 | -476 | -93 | 19 | N/A |
| 8/31/2024 | 912 | -24 | -125 | -6 | N/A |
| 5/31/2024 | 924 | -9 | -76 | 35 | N/A |
| 2/29/2024 | 929 | 2 | -13 | 99 | N/A |
| 11/30/2023 | 919 | 12 | 17 | 113 | N/A |
| 8/31/2023 | 919 | -27 | -5 | 78 | N/A |
| 5/31/2023 | 822 | -23 | -25 | 41 | N/A |
| 2/28/2023 | 721 | -13 | -82 | -30 | N/A |
| 11/30/2022 | 631 | -16 | -50 | -6 | N/A |
| 8/31/2022 | 531 | 36 | -5 | 31 | N/A |
| 5/31/2022 | 527 | 48 | 44 | 68 | N/A |
| 2/28/2022 | 514 | 49 | 50 | 70 | N/A |
| 11/30/2021 | 503 | 57 | 54 | 75 | N/A |
| 8/31/2021 | 487 | 62 | 55 | 79 | N/A |
| 5/31/2021 | 468 | 61 | 54 | 81 | N/A |
| 2/28/2021 | 450 | 61 | 58 | 85 | N/A |
| 11/30/2020 | 433 | 60 | 71 | 93 | N/A |
| 8/31/2020 | 426 | 61 | 65 | 87 | N/A |
| 5/31/2020 | 418 | 59 | 62 | 86 | N/A |
| 2/29/2020 | 419 | 59 | 62 | 81 | N/A |
| 11/30/2019 | 417 | 60 | N/A | 72 | N/A |
| 8/31/2019 | 416 | 60 | N/A | 71 | N/A |
| 5/31/2019 | 414 | 60 | N/A | 64 | N/A |
| 2/28/2019 | 413 | 62 | N/A | 66 | N/A |
| 11/30/2018 | 410 | 65 | N/A | 74 | N/A |
| 8/31/2018 | 403 | 66 | N/A | 67 | N/A |
| 5/31/2018 | 398 | 63 | N/A | 69 | N/A |
| 2/28/2018 | 389 | 58 | N/A | 62 | N/A |
| 11/30/2017 | 382 | 52 | N/A | 58 | N/A |
| 8/31/2017 | 372 | 46 | N/A | 59 | N/A |
| 5/31/2017 | 358 | 44 | N/A | 60 | N/A |
| 2/28/2017 | 353 | 41 | N/A | 53 | N/A |
| 11/30/2016 | 341 | 39 | N/A | 44 | N/A |
| 8/31/2016 | 330 | 37 | N/A | 49 | N/A |
| 5/31/2016 | 321 | 37 | N/A | 35 | N/A |
| 2/29/2016 | 310 | 36 | N/A | 38 | N/A |
| 11/30/2015 | 301 | 35 | N/A | 41 | N/A |
| 8/31/2015 | 290 | 34 | N/A | 40 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachting is dat NEOG de komende 3 jaar verliesgevend zal blijven.
Winst versus markt: De verwachting is dat NEOG de komende 3 jaar verliesgevend zal blijven.
Hoge groeiwinsten: De verwachting is dat NEOG de komende 3 jaar verliesgevend zal blijven.
Omzet versus markt: De omzet van NEOG zal naar verwachting de komende 3 jaar dalen ( -1.3% per jaar).
Hoge groei-inkomsten: De omzet van NEOG zal naar verwachting de komende 3 jaar dalen ( -1.3% per jaar).
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van NEOG naar verwachting over 3 jaar hoog zal zijn
Ontdek groeibedrijven
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/06/23 15:00 |
| Aandelenkoers aan het einde van de dag | 2026/06/23 00:00 |
| Inkomsten | 2026/02/28 |
| Jaarlijkse inkomsten | 2025/05/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Neogen Corporation wordt gevolgd door 16 analisten. 4 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Paul Knight | Brean Capital Historical (Janney Montgomery) |
| Robert Labick | CJS Securities, Inc. |
| David Westenberg | CL King & Associates, Inc. |